Evoq Remedies has informed that pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, the Stock Exchange BSE Limited (‘BSE’) has issued In-principle approval letter vide Ref: LOO/PREF/ DA/FIP /405/2024-25 dated 11th June, 2024 for the issue of 1,13,00,000 Equity shares. The In-principle approval letter received from the Stock Exchange, BSE is enclosed.
The above information is a part of company’s filings submitted to BSE.